Indication Global
Market Size
Pre
Clinical
Phase
Ib
Phase
IIb
Support for EU Conditional
Marketing Approval
Submission
Post EU
Marketing
US Phase 3
Organ failure associated with Sepsis $33B   Completed Phase II Initiated
Q1 2021
Completion of Phase
II Q4 2022
 
               
ARDS associated with severe/critical COVID-19 $1B (COVID)   Completed
COVID-19
Phase II Completed
COVID-19
Completion of Phase
IIb Q4 2023/Q1 2023
 
               
Solid tumors in combination with chemotherapy, immune checkpoints $4B   Phase Ib
Q1 2022
     
               

Recent Publications